Effect of nicotine mouth spray on urges to vape: A randomized, placebo-controlled, pharmacodynamic clinical trial in exclusive e-cigarette users.

What Was Tested

Researchers studied Therapeutic nicotine (patch, non-peptide) in this randomized controlled trial publication.

To determine whether nicotine mouth spray provides rapid and prolonged relief of urges to vape and measure the steady-state plasma nicotine levels during vaping and ad libitum mouth spray usage in e-cigarette users.

Who Took Part

By PubMed's age tags, the people studied were young adults and adults, both men and women.

How the Study Was Run

In design terms this was a randomized, double-blind, placebo-controlled and parallel-group study.

Because people in this Therapeutic nicotine (patch, non-peptide) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

As a double-blind Therapeutic nicotine (patch, non-peptide) study, the assignments were hidden from both participants and investigators until the end.

The comparison arm used a placebo, so changes seen with Therapeutic nicotine (patch, non-peptide) could be set against what happens without it.

The Therapeutic nicotine (patch, non-peptide) group and the comparison group ran side by side rather than switching.

Randomized, parallel group, double-blind trial.

The primary outcome measured average change from baseline in urges to vape ratings during the first hour.

What Was Measured

PubMed files the paper under topics including Vaping, Electronic Nicotine Delivery Systems, Nicotine, Oral Sprays and Nicotinic Agonists.

The authors tagged it with the keywords ENDS, NRT, RCT, craving relief, e‐cigarettes and urge to vape.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Therapeutic nicotine (patch, non-peptide).

Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2025 (Addiction (Abingdon, England)), a journal based in England.

More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.